Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons.
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are characterized by intraneuronal deposition of the nuclear TAR DNA-binding protein 43 (TDP-43) caused by unknown mechanisms. Here, we studied TDP-43 in primary neurons under different stress conditions and found that only proteasome inhibition by MG-132 or lactacystin could induce significant cytoplasmic accumulation of TDP-43, a histopathological hallmark in disease. This cytoplasmic accumulation was accompanied by phosphorylation, ubiquitination and aggregation of TDP-43, recapitulating major features of disease. Proteasome inhibition produced similar effects in both hippocampal and cortical neurons, as well as in immortalized motor neurons. To determine the contribution of TDP-43 to cell death, we reduced TDP-43 expression using small interfering RNA (siRNA), and found that reduced levels of TDP-43 dose-dependently rendered neurons more vulnerable to MG-132. Taken together, our data suggests a role for the proteasome in subcellular localization of TDP-43, and possibly in disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“proteasome inhibition using MG-132 leads to the cytoplasmic aggregation of TAR DNA-binding protein 43 (TDP-43) in cultured hippocampal and cortical neurons and in immortalized motor neurons (van Eersel et al., 2011).”
From Proteasome dysfunction induces muscle growth defects and protein aggregation (2014) · cites this paper as van Eersel et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 8×
“Since neurons are the primary cell type affected in FTLD-U and ALS, we tested the effects of proteasome inhibition on endogenous TDP-43 in primary cortical and hippocampal neurons or immortalized motor neurons.”
BackgroundResultInfluentialAssociation of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Protein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454 · cited 1×
“Pathological protein aggregates are frequently surrounded by proteasomes and lysosomes, however, these fail to fully remove the deposits [44,45].”
BackgroundArai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.093 · Cited by 2,732 · cited 1×
“Similar ubiquitin-positive inclusions are also found in motor neurons and some other neurons in ALS, and can contain either aggregated TDP-43 [11,12] and/or FUS [13].”
BackgroundTDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis
Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., Ackerley, S., Durnall, J. C., Williams, K. L., Buratti, E., et al. (2008) · Science · doi:10.1126/science.1154584 · Cited by 2,630 · cited 2×
“Cell culture, as well as yeast and animal models have provided insights into TDP-43 pathology [17,18,20,40,41,42].”
BackgroundBrooks, B. R. (1994) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)90191-0 · Cited by 2,140 · cited 1×
“ALS often leads to death within three years of diagnosis [1,2].”
BackgroundMutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821
Self-citationThe roles of intracellular protein-degradation pathways in neurodegeneration
Rubinsztein, D. C. (2006) · Nature · doi:10.1038/nature05291 · Cited by 1,625 · cited 2×
“Proteasome dysfunction has been implicated in several neurodegenerative disorders, including ALS [43,46].”
BackgroundTARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis
Kabashi, E., Valdmanis, P. N., Dion, P., Spiegelman, D., McConkey, B. J., Velde, C. V., Bouchard, J.-P., Lacomblez, L., Pochigaeva, K., Salachas, F., et al. (2008) · Nature Genetics · doi:10.1038/ng.132 · Cited by 1,544 · cited 4×
“Cell culture, as well as yeast and animal models have provided insights into TDP-43 pathology [17,18,20,40,41,42].”
BackgroundResultInfluential
Cited by
ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair
Klim, J. R., Williams, L. A., Limone, F., Guerra San Juan, I., Davis-Dusenbery, B. N., Mordes, D. A., Burberry, A., Steinbaugh, M. J., Gamage, K. K., Kirchner, R., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0300-4 · Cited by 653
Protein aggregation in amyotrophic lateral sclerosis
Blokhuis, A. M., Groen, E. J. N., Koppers, M., van den Berg, L. H., & Pasterkamp, R. J. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1125-6 · Cited by 579
“Consistently, proteasome inhibition has been found to increase endogenous TDP-43 levels, blocks degradation of overexpressed TDP-43 C-terminal fragments and enhances toxicity [88, 155, 194, 220].”
BackgroundRNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43
Mann, J. R., Gleixner, A. M., Mauna, J. C., Gomes, E., DeChellis-Marks, M. R., Needham, P. G., Copley, K. E., Hurtle, B., Portz, B., Pyles, N. J., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.048 · Cited by 537
The role of TDP-43 mislocalization in amyotrophic lateral sclerosis
Suk, T. R., & Rousseaux, M. W. C. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00397-1 · Cited by 450
TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets
Scotter, E. L., Chen, H.-J., & Shaw, C. E. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0338-x · Cited by 382
“Enhanced levels of TDP-43 in the cytoplasm can occur downstream of ALS-linked mutations [16, 39, 60, 145, 146], cellular stress [20, 136–138], or impaired degradation [147].”
Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis
Dasuri, K., Zhang, L., & Keller, J. N. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.09.016 · Cited by 371
Scotter, E. L., Vance, C., Nishimura, A. L., Lee, Y.-B., Chen, H.-J., Urwin, H., Sardone, V., Mitchell, J. C., Rogelj, B., Rubinsztein, D. C., et al. (2014) · Journal of Cell Science · doi:10.1242/jcs.140087 · Cited by 268
“It has previously been shown that inhibition of the UPS can induce aggregates of full-length TDP-43 (Kim et al., 2012; van Eersel et al., 2011).”
BackgroundPathomechanisms of TDP‐43 in neurodegeneration
Gao, J., Wang, L., Huntley, M. L., Perry, G., & Wang, X. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14327 · Cited by 228
“…proteasome system (UPS) or autophagy pathways was sufficient to cause TDP-43 cytoplasmic accumulation and neurotoxicity (Wang et al. 2010; van Eersel et al. 2011), while over-expression of p62 reduced TDP-43 cytoplasmic accumulation in both an UPS- and autophagy- dependent manner (Brady et…”
BackgroundTDP-43: gumming up neurons through protein–protein and protein–RNA interactions
Buratti, E., & Baralle, F. E. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.03.003 · Cited by 194
The Pathobiology of TDP-43 C-Terminal Fragments in ALS and FTLD
Berning, B. A., & Walker, A. K. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00335 · Cited by 193
Religion Does Matter for Climate Change Attitudes and Behavior
Morrison, M., Duncan, R., & Parton, K. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134868 · Cited by 186
Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones
Udan-Johns, M., Bengoechea, R., Bell, S., Shao, J., Diamond, M. I., True, H. L., Weihl, C. C., & Baloh, R. H. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt408 · Cited by 151
“This is in keeping with the observation that TDP-43 aggregation can be induced by proteasome inhibition (16,61,62) or accumulation of proteins in the secretory pathway by tunicamycin (63).”
BackgroundTDP-43/FUS in motor neuron disease: Complexity and challenges
Guerrero, E. N., Wang, H., Mitra, J., Hegde, P. M., Stowell, S. E., Liachko, N. F., Kraemer, B. C., Garruto, R. M., Rao, K. S., & Hegde, M. L. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.09.004 · Cited by 140
“Ubiquitination of TDP-43 may be a late event in disease pathogenesis because most TDP-43 inclusions are not ubiquitinated in early disease stages (van Eersel et al, 2011).”
BackgroundPathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders
Janssens, J., & Van Broeckhoven, C. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt349 · Cited by 139
In vitro prion-like behaviour of TDP-43 in ALS
Smethurst, P., Newcombe, J., Troakes, C., Simone, R., Chen, Y.-R., Patani, R., & Sidle, K. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.08.007 · Cited by 139
“To date studies have largely utilised the overexpression of mutant, expanded, deleted or truncated constructs and chemical modification to induce the aggregation of TDP-43 (Johnson et al., 2009; Nonaka et al., 2009a, 2009b; van Eersel et al., 2011; Wang et al., 2013).”
MethodSaucier, D., Wajnberg, G., Roy, J., Beauregard, A.-P., Chacko, S., Crapoulet, N., Fournier, S., Ghosh, A., Lewis, S. M., Marrero, A., et al. (2019) · Brain Research · doi:10.1016/j.brainres.2018.12.016 · Cited by 119
Smethurst, P., Risse, E., Tyzack, G. E., Mitchell, J. S., Taha, D. M., Chen, Y.-R., Newcombe, J., Collinge, J., Sidle, K., & Patani, R. (2020) · Brain · doi:10.1093/brain/awz419 · Cited by 111
Michalska, P., & Leon, R. M. (2020) · Antioxidants · doi:10.3390/antiox9080740 · Cited by 119
Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD
Wood, A., Gurfinkel, Y., Polain, N., Lamont, W. G., & Rea, S. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094705 · Cited by 111
“Of note, inhibition of the proteasome, but not other stress conditions, induced the phosphorylation, ubiquitination and cytoplasmic aggregation of TDP-43, epitomizing ALS and FTLD TDP-43 proteinopathies [182].”
BackgroundHans, F., Fiesel, F. C., Strong, J. C., Jäckel, S., Rasse, T. M., Geisler, S., Springer, W., Schulz, J. B., Voigt, A., & Kahle, P. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.561704 · Cited by 94
The Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimer’s Disease
Sulistio, Y. A., & Heese, K. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-9063-4 · Cited by 99
Loss of TDP‐43 oligomerization or RNA binding elicits distinct aggregation patterns
Pérez‐Berlanga, M., Wiersma, V. I., Zbinden, A., Vos, L. D., Wagner, U., Foglieni, C., Mallona, I., Betz, K. M., Cléry, A., Weber, J., et al. (2023) · The EMBO Journal · doi:10.15252/embj.2022111719 · Cited by 107
Does a loss of TDP-43 function cause neurodegeneration?
Xu, Z.-S. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-27 · Cited by 92
m1A in CAG repeat RNA binds to TDP-43 and induces neurodegeneration
Sun, Y., Dai, H., Dai, X., Yin, J., Cui, Y., Liu, X., Gonzalez, G. M., Yuan, J. J., Tang, F., Wang, N., et al. (2023) · Nature · doi:10.1038/s41586-023-06701-5 · Cited by 91
Preserving Lysosomal Function in the Aging Brain: Insights from Neurodegeneration
Peng, W., Minakaki, G., Nguyen, M., & Krainc, D. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00742-3 · Cited by 79
Sternburg, E. L., da Silva, L. A. G., & Dormann, D. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2021.07.004 · Cited by 83
Thomas, M., Alegre-Abarrategui, J., & Wade-Martins, R. (2013) · Brain · doi:10.1093/brain/awt030 · Cited by 76
“…comes from studies in primary hippocampal cortical neurons and motor neuron lines in which the direct manipulation of protein degradation pathways by the addition of proteasome inhibitors, or expression of mutant VCP, results in TDP-43 relocalization (Ritson et al., 2010; van Eersel et al., 2011).”
BackgroundThe role of TDP-43 in the pathogenesis of ALS and FTLD
Baralle, M., Buratti, E., & Baralle, F. E. (2013) · Biochemical Society Transactions · doi:10.1042/bst20130186 · Cited by 76
TDP-43 pathology: From noxious assembly to therapeutic removal
Keating, S. S., Gil, R. S., Swanson, M. E. V., Scotter, E. L., & Walker, A. K. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102229 · Cited by 89
Oiwa, K., Watanabe, S., Onodera, K., Iguchi, Y., Kinoshita, Y., Komine, O., Sobue, A., Okada, Y., Katsuno, M., & Yamanaka, K. (2023) · Science Advances · doi:10.1126/sciadv.adf6895 · Cited by 82
Proteostatic imbalance and protein spreading in amyotrophic lateral sclerosis
Cicardi, M. E., Marrone, L., Azzouz, M., & Trotti, D. (2021) · The EMBO Journal · doi:10.15252/embj.2020106389 · Cited by 80
“In the context of ALS, pharmacological inhibition of the proteasomes via MG132 or lactacystin could induce significant accumulation and aggregation of TDP-43 protein in cultured cells (Nonaka et al, 2009; van Eersel et al, 2011).”
Impaired protein degradation in FTLD and related disorders
Götzl, J. K., Lang, C. M., Haass, C., & Capell, A. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.04.008 · Cited by 81
Cell‐to‐cell transmission of C9orf72 poly‐(Gly‐Ala) triggers key features of ALS/FTD
Khosravi, B., LaClair, K. D., Riemenschneider, H., Zhou, Q., Frottin, F., Mareljic, N., Czuppa, M., Farny, D., Hartmann, H., Michaelsen, M., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019102811 · Cited by 82
“Proteasome inhibitors promote TDP-43 pathology in vitro (van Eersel et al , 2011), but DPR and TDP-43 inclusions rarely occur within the same cell in patients (Mori et al , 2013).”
Proteasome dysfunction induces muscle growth defects and protein aggregation
Kitajima, Y., Tashiro, Y., Suzuki, N., Warita, H., Kato, M., Tateyama, M., Ando, R., Izumi, R., Yamazaki, M., Abe, M., et al. (2014) · Journal of Cell Science · doi:10.1242/jcs.150961 · Cited by 79
“Proteasomal proteolysis is important in several organs; for example, proteasome inhibition using MG-132 leads to the cytoplasmic aggregation of TAR DNA-binding protein 43 (TDP- 43) in cultured hippocampal and cortical neurons and in immortalized motor neurons (van Eersel et al., 2011).”
BackgroundConnecting TDP-43 Pathology with Neuropathy
Klim, J. R., Pintacuda, G., Nash, L. A., Juan, I. G. S., & Eggan, K. C. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2021.02.008 · Cited by 77
Amyloid-β oligomers as a template for secondary amyloidosis in Alzheimer's disease
Guerrero-Muñoz, M. J., Castillo-Carranza, D. L., Krishnamurthy, S., Paulucci-Holthauzen, A. A., Sengupta, U., Lasagna-Reeves, C. A., Ahmad, Y., Jackson, G. R., & Kayed, R. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.008 · Cited by 67
Ubiquitin Homeostasis Is Disrupted in TDP-43 and FUS Cell Models of ALS
Farrawell, N. E., McAlary, L., Lum, J. S., Chisholm, C. G., Warraich, S. T., Blair, I. P., Vine, K. L., Saunders, D. N., & Yerbury, J. J. (2020) · iScience · doi:10.1016/j.isci.2020.101700 · Cited by 70
TDP-43 Regulates the Microprocessor Complex Activity During In Vitro Neuronal Differentiation
Di Carlo, V., Grossi, E., Laneve, P., Morlando, M., Dini Modigliani, S., Ballarino, M., Bozzoni, I., & Caffarelli, E. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8564-x · Cited by 63
Naskar, A., Nayak, A., Salaikumaran, M. R., Vishal, S. S., & Gopal, P. P. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1242925 · Cited by 63
Ferrer, I. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.07.004 · Cited by 62
Oxr1 improves pathogenic cellular features of ALS-associated FUS and TDP-43 mutations
Finelli, M. J., Liu, K. X., Wu, Y., Oliver, P. L., & Davies, K. E. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv104 · Cited by 73
Expression of FSHD‐related DUX4‐FL alters proteostasis and induces TDP‐43 aggregation
Homma, S. T., Beermann, M. L., Boyce, F. M., & Miller, J. B. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.158 · Cited by 55
“>24 h).(43) In our studies, we found that both exogenous and endogenous DUX4-FL induced only nuclear aggregates of the endogenously expressed TDP-43 protein.”
BackgroundMorrison, M., Parton, K. A., & Hine, D. W. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197988 · Cited by 71
Hans, F., Eckert, M., von Zweydorf, F., Gloeckner, C. J., & Kahle, P. J. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003440 · Cited by 54
“The CTFs are degraded rapidly by the proteasome after their formation (24, 38) and become insoluble if they are stabilized by proteasomal inhibition (19, 26, 29, 39).”
BackgroundTDP-43 regulates endogenous retrovirus-K viral protein accumulation
Manghera, M., Ferguson-Parry, J., & Douville, R. N. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.06.017 · Cited by 53
Ishii, T., Kawakami, E., Endo, K., Misawa, H., & Watabe, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179375 · Cited by 59
Molecular Dissection of TDP-43 as a Leading Cause of ALS/FTLD
Tamaki, Y., & Urushitani, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012508 · Cited by 57
van Eersel, J., Stevens, C. H., Przybyla, M., Gladbach, A., Stefanoska, K., Chan, C. K., Ong, W., Hodges, J. R., Sutherland, G. T., Kril, J. J., et al. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12233 · Cited by 50
Self-citationTargeting TDP‐43 proteinopathy with drugs and drug‐like small molecules
Buratti, E. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15148 · Cited by 51
Babazadeh, A., Rayner, S. L., Lee, A., & Chung, R. S. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102085 · Cited by 52
“First, protein clearance systems are a complex interconnected network, and administration of small molecules that might target one specific pathway may have adverse effects on other pathways, illustrating how it would be important to investigate all protein degradation pathways together for a…”
BackgroundLee, S. M., Asress, S., Hales, C. M., Gearing, M., Vizcarra, J. C., Fournier, C. N., Gutman, D. A., Chin, L., Li, L., & Glass, J. D. (2019) · Brain Communications · doi:10.1093/braincomms/fcz014 · Cited by 45
Cascella, R., Fani, G., Capitini, C., Rusmini, P., Poletti, A., Cecchi, C., & Chiti, F. (2017) · The FASEB Journal · doi:10.1096/fj.201700292rr · Cited by 44
Chua, S. W., Cornejo, A., van Eersel, J., Stevens, C. H., Vaca, I., Cueto, M., Kassiou, M., Gladbach, A., Macmillan, A., Lewis, L., et al. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00433 · Cited by 41
Self-citationGao, J., Wang, L., Gao, C., Arakawa, H., Perry, G. L., & Wang, X. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165580 · Cited by 42
“Although no study shows the proteasome-dependent degradation of matrix facing inner mitochondrial membrane (IMM) proteins, both the ubiquitin proteasome system (UPS) and autophagy pathways have been implicated in cytosolic TDP-43 clearance [52, 53].”
BackgroundPathological mechanisms of amyotrophic lateral sclerosis
Hu, Y., Chen, W., Wei, C., Jiang, S., Li, S., Wang, X., & Xu, R. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.382985 · Cited by 48
Caccamo, A., Shaw, D. M., Guarino, F., Messina, A., Walker, A. W., & Oddo, S. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv193 · Cited by 35
The Role of Ubiquitin in Regulating Stress Granule Dynamics
Krause, L. J., Herrera, M. G., & Winklhofer, K. F. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.910759 · Cited by 39
Targeting RNA Binding Proteins Involved in Neurodegeneration
Romano, M., & Buratti, E. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113497256 · Cited by 35
Verde, E. M., Secco, V., Ghezzi, A., Mandrioli, J., & Carra, S. (2025) · Cells · doi:10.3390/cells14100680 · Cited by 38
“The accumulation of poly-ubiquitinated insoluble TDP-43 is also a very common feature of pathological inclusion in ALS-FTD, likely caused by an impairment of the protein degradation systems [297,307–309].”
Baloh, R. H. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32835a269b · Cited by 36
TDP-43 proteinopathy in ALS is triggered by loss of ASRGL1 and associated with HML-2 expression
Montojo, M. G., Fathi, S., Rastegar, C. T., Simula, E. R., Doucet-O’Hare, T. T., Cheng, Y.-H. H., Abrams, R. P. M., Pasternack, N., Malik, N., Bachani, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48488-7 · Cited by 36
“Inhibition of the ubiquitin-proteasome system by treat- mentwithepoxomicinorMG132wasassociatedwithcytoplasmicTDP-43 fragments in both immortalized neuronal cell lines and primary hippocampal and cortical cultures 51 .”
BackgroundGlobal Climate Change: A Social Identity Perspective on Informational and Structural Interventions
Ferguson, M. A., McDonald, R. I., & Branscombe, N. R. (2016) · Peace psychology book series · doi:10.1007/978-3-319-29869-6_10 · Cited by 42
Picher‐Martel, V., Renaud, L., Bareil, C., & Julien, J. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1411-3 · Cited by 39
Casterton, R., Hunt, R. J., & Fanto, M. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.02.018 · Cited by 38
Intercellular transmission of pathogenic proteins in ALS: Exploring the pathogenic wave
Arnold, F. J., Nguyen, A., Bedlack, R., Bennett, C. L., & Spada, A. R. L. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106218 · Cited by 31
Targeting TDP-43 in neurodegenerative diseases
Budini, M., Baralle, F. E., & Buratti, E. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.896905 · Cited by 31
“showed that the incubation of primary cortical neurons with MG-132 and lactacystin triggered TDP-43 aggregation making the cells more sensitive to TDP-43 downregulation [80].”
BackgroundHo, P., Hsieh, T., & Tsai, K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102441 · Cited by 29
Therapeutic and diagnostic challenges for frontotemporal dementia
Dâ€TMAlton, S., & Lewis, J. M. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00204 · Cited by 26
“Reduction of TDP-43 in primary neuronal cell culture also increases sensitivity to toxic proteasome inhibition (van Eersel et al., 2011).”
BackgroundTDP-43 is a ubiquitylation substrate of the SCFcyclin F complex
Rayner, S. L., Yang, S., Farrawell, N. E., Jagaraj, C. J., Cheng, F., Davidson, J. M., Luu, L., García‐Redondo, A., Rábano, A., Borrego‐Hernández, D., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105673 · Cited by 26
“…including SOD1 (Deng et al., 1993; Rosen et al., 1993), VCP (Watts et al., 2004), TARDBP (Sreedharan et al., 2008), FUS (Kwiatkowski et al., 2009; Vance et al., 2009), OPTN (Maruyama et al., 2010), SQSTM1 (Fecto et al., 2011), UBQLN2 (Deng et al., 2011), MATR3 (Johnson et al., 2014) and TBK1…”
Araki, W., Minegishi, S., Motoki, K., Kume, H., Hohjoh, H., Araki, Y. M., & Tamaoka, A. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8644-6 · Cited by 28
Analysis of β-N-methylamino- l -alanine (L-BMAA) neurotoxicity in rat cerebellum
Muñoz‐Sáez, E., de Munck, E., Portero, R. M. A., Martínez, A., Alados, M. T. S., & Miguel, B. G. (2015) · NeuroToxicology · doi:10.1016/j.neuro.2015.04.001 · Cited by 27
Jiang, L., Zhang, X.-L., & Hu, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212380 · Cited by 30
Lin, P., Folorunso, O. O., Taglialatela, G., & Pierce, A. P. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23725 · Cited by 24
Ke, Y. D., van Hummel, A., Au, C. G., Chan, G., Lee, W. S., van der Hoven, J., Przybyla, M., Deng, Y., Sabale, M., Morey, N., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.01.022 · Cited by 24
Self-citationKotarba, S., Kozłowska, M., Scios, M., Saramowicz, K., Barczuk, J., Granek, Z., Siwecka, N., Wiese, W., Golberg, M., Galita, G., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910797 · Cited by 26
“As a result of these posttranslational modifications, TDP-43 may accumulate, and form aggregates localized in the cytoplasm, often co-localizing with NFTs and senile plaques [223].”
BackgroundAltered Proteostasis in Neurodegenerative Tauopathies
Papanikolopoulou, K., & Skoulakis, E. M. C. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-38266-7_7 · Cited by 29
Cassiano, C., Esposito, R., Tosco, A., Zampella, A., D’Auria, M. V., Riccio, R., Casapullo, A., & Monti, M. C. (2013) · Chemical Communications · doi:10.1039/c3cc45454a · Cited by 21
TDP-43, a protein central to amyotrophic lateral sclerosis, is destabilized by tankyrase-1 and -2
McGurk, L., Rifai, O. M., & Bonini, N. M. (2020) · Journal of Cell Science · doi:10.1242/jcs.245811 · Cited by 24
Jayakumar, A. R., Tong, X., Shamaladevi, N., Barcelona, S., Gaidosh, G., Agarwal, A. N., & Norenberg, M. D. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13867 · Cited by 22
Degradomics in Neurotrauma: Profiling Traumatic Brain Injury
Abou‐El‐Hassan, H., Sukhon, F., Assaf, E. J., Bahmad, H. F., Abou‐Abbass, H., Jourdi, H., & Kobeissy, F. H. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6952-4_4 · Cited by 20
Characterization of Dopaminergic System in the Striatum of Young Adult Park2−/− Knockout Rats
Gemechu, J. M., SHARMA, A. K., Yu, D., Xie, Y., Merkel, O. M., & Moszczyńska, A. (2018) · Scientific Reports · doi:10.1038/s41598-017-18526-0 · Cited by 17
The effect of G-quadruplexes on TDP43 condensation, distribution, and toxicity
Oldani, E. G., Caicedo, K. M. R., Herda, M. E. S., Sachs, A. H., Chapman, E. G., Kumar, S., Linseman, D. A., & Horowitz, S. A. (2024) · Structure · doi:10.1016/j.str.2025.05.006 · Cited by 19
Watabe, K., Akiyama, K., Kawakami, E., Ishii, T., Endo, K., Yanagisawa, H., Sango, K., & Tsukamoto, M. (2013) · Neuropathology · doi:10.1111/neup.12058 · Cited by 20
“In these, inhibition of proteasome or autophagy has been reported to induce aggregate formation when TDP-43 plasmids were used.(31,32,34,39) Depletion of ESCRT molecules TSG101 and VPS24 by siRNA in HeLa cells also induced cytoplasmic TDP-43/ubiquitin/p62-positive aggregate formation.”
BackgroundTargeting Segments in the Australian Community to Increase Support for Climate Change Policy
Morrison, M., Duncan, R., & Parton, K. A. (2013) · Australasian Marketing Journal (AMJ) · doi:10.1016/j.ausmj.2013.09.001 · Cited by 23
Proteomics elucidating physiological and pathological functions of TDP‐43
Morato, J. G., Gloeckner, C. J., & Kahle, P. J. (2023) · PROTEOMICS · doi:10.1002/pmic.202200410 · Cited by 18
“Cellstreatedwithproteasomeinhibitorshowedaccumulation of poly-ubiquitinylated, insoluble TDP-43 [124, 150].”
Ueda, T., Takeuchi, T., Fujikake, N., Suzuki, M., Minakawa, E. N., Ueyama, M., Fujino, Y., Kimura, N., Nagano, S., Yokoseki, A., et al. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01729-8 · Cited by 16
“Previous studies have reported that the ubiquitin–proteasome system plays an important role in the clearance of stress granule components, and that impairment of proteasomal degradation leads to the aberrant accumulation of TDP-43 aggregates in the cytoplasm [34, 40, 42].”
BackgroundNg, J. S. W., Hanspal, M. A., Matharu, N. S., de Barros, T. P., Esbjörner, E. K., Wilson, M. R., Yerbury, J. J., Dobson, C. M., & Kumita, J. R. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00592 · Cited by 13
Smeele, P. H., Cesare, G., & Vaccari, T. (2024) · Cells · doi:10.3390/cells13020178 · Cited by 12
“…the 26S proteasome has also been shown to lead to the cytoplasmic In addition to being possible targets of UPS-mediated degradation, DPRs in fact appear to inhibit UPS activity [13–15 and aggregation of TAR DNA-binding protein 43 (TDP43) [38,39], a second aggregation-prone protein , associated 33–”
BackgroundZnaidi, R., Massiani-Beaudoin, O., Mailly, P., Monnet, H., Bonnifet, T., The Brainbank Neuro-CEB Neuropathology Network, Joshi, R. L., & Fuchs, J. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149579 · Cited by 14
“One consequence we identified is the cytoplasmic accumulation of TDP-43 which could favor its aggregation (Van Eersel et al., 2011), one of the hallmarks of several NDs (Zhang et al., 2015; Neumann et al., 2006; Aizawa et al., 2019).”
Watanabe, S., & Yamanaka, K. (2025) · BioEssays · doi:10.1002/bies.70016 · Cited by 15
“Stressors that disrupt proteostasis [53, 54], such as the ER stressor tunicamycin [55] or the proteasomal inhibitor MG-132 [56], induce TDP-43 aggregation.”
Atmaramani, R., Dreossi, T., Ford, K., Gan, L., Mitchell, J. M., Tu, S., Velayutham, J., Zeng, H., Chickering, M., Soare, T., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.04.574270 · Cited by 14
“Bortezomib inhibits proteasomal degradation, a key pathway relevant to intracellular aggregation of insoluble TDP-43 (van Eersel et al., 2011).”
BackgroundNarayan, M., Peralta, D. A., Gibson, C. L., Zitnyar, A., & Jinwal, U. K. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.04.012 · Cited by 10
Bhandare, V. V., & Ramaswamy, A. (2016) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2016.01.001 · Cited by 9
Molecular Visualization of Neuronal TDP43 Pathology In SituPreprint
Erwin, A. L., Fernandez, M. G., Chang, M. L., Attili, D., Bekier, M., Pinarbasi, E. S., Russ, J. E., Sutanto, R., Thomas, D., Shen, X., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.19.608477 · Cited by 10
“Brains from individual pups in each litter were pooled to maximize cell counts prior to plating; as a result, primary cortical neurons used for all studies include an even mix of cells from both male and female pups.”
Kochen, N. N., Murray, M., Zafari, S., Vunnam, N., Liao, E. E., Chen, L., Braun, A. R., & Sachs, J. N. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00266 · Cited by 9
Leskelä, S., Huber, N., Hoffmann, D. B., Rostalski, H., Remes, A. M., Takalo, M., Hiltunen, M., & Haapasalo, A. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.119021 · Cited by 11
“as proteins such as TDP-43 [15], which is a known UPS substrate [16,17].”
BackgroundContext-dependent Interactors Regulate TDP-43 Dysfunction in ALS/FTLDPreprint
Xie, L., Zhu, Y., Hurtle, B. T., Wright, M., Robinson, J. L., Mauna, J. C., Brown, E. E., Ngo, M., Bergmann, C. A., Xu, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.07.646890 · Cited by 17
Shen, D., Vincent, A. J., Udine, E., Buhidma, Y., Anoar, S., Tsintzas, E., Maeland, M. E., Xu, D., Carcolé, M., Osumi-Sutherland, D., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115459 · Cited by 9
RNP2 of RNA Recognition Motif 1 Plays a Central Role in the Aberrant Modification of TDP-43
Takagi, S., Iguchi, Y., Katsuno, M., Ishigaki, S., Ikenaka, K., Fujioka, Y., Honda, D., Niwa, J.-I., Tanaka, F., Watanabe, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066966 · Cited by 6
Temussi, P. A., Tartaglia, G. G., & Pastore, A. (2021) · BioEssays · doi:10.1002/bies.202100031 · Cited by 6
Metadata
- Authors
- van Eersel, J., Ke, Y. D., Gladbach, A., Bi, M., Götz, J., Kril, J. J., & Ittner, L. M.
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- Ittner, Lars M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-07-29
- Volume
- 6
- Issue
- 7
- Pages
- e22850
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3146516
- OpenAlex
- W2088821814
- Cited by
- 130
- References
- 73
- Citations by year
- 2026: 15 · 2025: 9 · 2024: 12 · 2023: 9 · 2022: 6 · 2021: 7 · 2020: 8 · 2019: 8 · 2018: 8 · 2017: 5 · 2016: 10 · 2015: 9 · 2014: 9 · 2013: 11 · 2012: 4
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Science Council
- Medical Research Council
- Australian Research Council
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Keywords
- TDP-43, proteasome inhibition, cytoplasmic accumulation, protein aggregation, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, neuronal stress, TDP-43 phosphorylation, ubiquitination, motor neurons, hippocampal neurons, cortical neurons, neurodegeneration
- MeSH terms
- Animals, Cell Nucleus, Cells, Cultured, Cytoplasm, DNA-Binding Proteins, Humans, Immunoenzyme Techniques, Leupeptins, Neurons, Phosphorylation, RNA, Messenger, Subcellular Fractions, Blotting, Western, Cysteine Proteinase Inhibitors, Cell Death, RNA, Small Interfering, Immunoprecipitation, Mice, Ubiquitination, Proteasome Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.